Proove® Biosciences Unveils New Logo Focused On The Nexus Of Healthcare

IRVINE, Calif., March 21, 2017 /PRNewswire/ -- Proove® Biosciences, Inc. is proud to unveil its new logo featuring the "nexus" as its centrally-defining feature. Proove®'s name is uniquely misspelled with double O's. In the previous logo, a double-helix appeared for those double O's; however, this led to mistaken thinking that Proove®'s profiles are solely reliant on genetics.

Proove® delivers on the promise of precision medicine for pain - the condition that lies at the nexus of health. Pain is the nation's most prevalent and expensive condition – more than cancer, diabetes and heart disease combined. Pain is the #1 reason why patients visit their physician, and the most widely prescribed medications in primary care. Pain is the only condition every clinician treats, and is a common measure in clinical trials. Yet, the standard of care is a subjective 1 to 10 scale or what Proove® CEO Brian Meshkin calls "Science by Emoji™" with smiley and frowny faces to assess pain. Proove® profiles demonstrate we can do better than these subjective assessments.

Meshkin explains, "For six months, our team has worked on this re-branding initiative. Some people look at our old logo and fail to understand that our predictive analytics involve clinical, environmental, lifestyle and genetic information. We're reminded that we live in a very superficial world. Just as many people have been discriminated against because of their skin color, gender and religion, it's very easy to fall into the trap of looking only at the surface of people, things, and ideas without taking the time and effort to delve deeper. This is where the adage 'Don't Judge a Book by Its Cover' comes from. Unfortunately, some people make uneducated conclusions without knowing the truth. Our hope is that this new logo will help people understand what we do."

Vice President of Commercial Operations Kirt Pfaff explains, "Clinicians use Proove® to better understand a patient's pain as well as predict risk and response to medications. Clinicians use Proove®'s predictive analytics to 'proove' the diagnosis, treatment and outcomes. Our new logo embodies our mission and the expectation that our name will become a verb in the universe of pain treatment."

About Proove Biosciences: Proove® Biosciences is the leader in precision medicine for the condition that lies at the nexus of health – pain. Proove® delivers precision medicine solutions for the nation's most prevalent and expensive health condition by investing heavily in research that has won awards from leading medical societies and been published in peer-reviewed journals.  Discovered by NIH-funded scientists, Proove® has translated into clinical practice the genetic variants and phenotypic factors contributing to pain sensitivity and chronic pain risk. Proove®'s medical advisory board is led by those NIH-funded researchers and the company has licensed some of its technology from leading academic centers, such as the University of North Carolina at Chapel Hill, the University of Utah, and other institutions. Positioned as The Healthcare Decision Company,™ Proove®'s patented technology platform combines genetic, clinical, environmental and lifestyle information to help clinicians better evaluate pain sensitivity, assess risk for opioid use disorder, predict therapeutic response to pain medications, and assess drug metabolism for the many medications used in chronic pain patients. Based in Irvine, California, Proove® has been recognized on the Inc. 500 and the Deloitte Technology Fast500 as one of the fastest growing companies in North America. For more information, please visit www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).

SOURCE Proove Biosciences, Inc.

Related Links

http://www.proove.com